About this policy
The comment period for the MolDX: Lab-Developed Tests for Inherited Cancer Syndromes DL38972 Local Coverage Determination (LCD) began on 05/20/2021 and ended on 07/31/2021. The notice period for L38972 begins on 06/23/2022 and will become effective on 08/08/2022. The title of the LCD was revised from MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes to MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. The comments below were received from the provider community.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.